Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02497820 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers

Study acronym: CaPP3 Israel
StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 2015 to Sep 2016
    • Collaborators: 2 to 4
    • Study title shortened, about 6 words
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A randomised double blind dose non-inferiority trial of a daily dose of 600mg versus 300mg versus 100mg of enteric coated aspirin as a cancer preventive in carriers of a germline pathological mismatch repair gene defect, Lynch Syndrome. Project 3 in the Cancer Prevention Programme (CaPP3).
Trial Details
NCT Number NCT02497820
Lead Sponsor Tel-Aviv Sourasky Medical Center
Collaborators: Rambam Health Care Campus, Rabin Medical Center, Soroka University Medical Center, Sheba Medical Center
Conditions
(from sponsor)		 Lynch Syndrome I (Site-specific Colonic Cancer)
Related terms Lynch syndrome I (site-specific colonic cancer)
Enrollment 1,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov